Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 19 June 2026
Revised 25 July 2026
Accepted 05 August 2026

Natural Resources for Human Health 2026, Vol. 6 (6): 499–517

KEYWORDS:
Pharmaceutical industry; medicine, Artificial intelligence, public health

Factors Influencing The Pharmaceutical Industry: A Comprehensive Review

Muhammad Akram[1], Marium Ahsan[2], Naveed Munir[3], Ho Soonmin[4]

[1]Department of Eastern Medicine, Government College University Faisalabad-Pakistan
[2]Department of Eastern Medicine, Superior University Lahore-Pakistan
[3]Department of Biomedical Lab Sciences, School of Health Sciences, University of Management and Technology, Lahore, Pakistan
[4]Faculty of Health and Life Sciences, INTI International University, Putra Nilai, 71800, Negeri Sembilan, Malaysia. soonmin.ho@newinti.edu.my

ABSTRACT: The pharmaceutical sector is essential for the health care systems of the world by producing prescription and over-the-counter medications to prevent or treat various medical conditions; however, that is not the only aspect of the sector; it is influenced by all of the available scientific, financial, political, technical, social, and ethical factors at play in our global economy. This article reviews the key factors impacting the pharmaceutical sector today. The article discusses the regulatory environment, R&D activities in the sector, the importance to the sector of IP, competitive pressure in terms of marketing/advertising, the effects of globalization on the market, the effect of technology on the market, the effect of healthcare policy on the sector, the pressures on pricing in the market, the effect of the supply chain on the practices of the sector, the sustainability of the industry in terms of the environment, and emerging technologies such as AI and personalized medicine. Together these factors continually change the landscape of the Pharmaceutical Industry because of the dynamic and interdependent nature of both internal and external forces within the entire global economy and therefore all participants/stakeholders in the industry must understand all the forces affecting the industry in order to bring about innovation, equity in terms of access to health care services, and to do so while fostering an equitable and viable diverse workforce in the sector.

INTRODUCTION

The Pharmaceutical Industry is an extremely heavily regulated and very intensive research segment of the global economy [1]. In addition to supporting and forming the foundation for modern health care systems, the pharmaceutical industry plays an essential role in providing solutions for preventing, treating, and curing disease. Breakthroughs in the fields of antibiotics and vaccines; biologic, gene therapy products, etc., have dramatically increased life expectancy and improved quality of life around the world. Impactful discoveries related to antimicrobial agents, cardiovascular products, oncology therapies, and immunization programs during the past 100 years have changed previously fatal conditions into either manageable or preventable diseases. The pharmaceutical industry, as a result, plays a principal role in both public health initiatives and economic development, job creation, and technological advancement. However, even with many important accomplishments over the years, there are numerous and continuously evolving challenges facing the pharmaceutical industry.

The drug development process is long, complex, and expensive, requiring large amounts of time and money invested in research and development, clinical trials, regulatory approvals, and post-marketing surveillance. Given these issues, only a small number of the compounds developed enter the marketplace as medicines and the regulatory requirements imposed on the pharmaceutical industry are extremely stringent for approval from the U. S. Rigorous FDA (Food and Drug Administration) and EMA (the European Medicines Agency) regulations impose strict standards of evaluation during the development of pharmaceuticals to ensure drug safety, effectiveness, and quality [2]. These regulations provide a level of protection for

consumers and help to keep the pharmaceuticals safe and effective. However, the costs associated with increased operational costs, development timelines, and associated costs due to regulations can be significant.

Competition has intensified for manufacturers of pharmaceuticals due to the rapid increase of generic drugs, biosimilars and biopharmaceutical companies in the pharmaceutical marketplace. The expiration of patents, price pressures and limitations on healthcare provider reimbursements have added to the challenges faced by manufacturers of pharmaceuticals in maintaining their profitability in a highly competitive industry. Additionally, public scrutiny relating to pharmaceutical pricing, ethical marketing practices and equitable access to medication has increased, creating additional reputation pressures on manufacturers of pharmaceuticals. Furthermore, global events, including but not limited to the COVID-19 pandemic; geopolitical tensions; disruptions to supply chains; and global economic instability have significantly impacted companies' strategic decisions and investment priorities within the pharmaceutical industry [3].

The purpose of this article is to examine the multidimensional influences affecting the global pharmaceutical industry. The article will provide an organized, comprehensive review of the factors that shape the growth, sustainability, competitiveness and future paths of the global pharmaceutical industry in an increasingly complex environment.

1.1 RESEARCH AND DEVELOPMENT (R&D) DYNAMICS

Research & Development (R&D) serves as both the foundation for and major driver of the pharmaceutical sector. R&D influences the scientific direction of each company, financial viability, competitive advantage and future viability [4]. Successfully completing the R&D cycle consists of converting basic science into safe, effective and commercially viable drugs via research. However, there are many different obstacles involved in R&D which means that R&D is one of the key factors that has the largest effect on the pharmaceutical industry.

1.1.1 Cost of Drug Development

Developing new drugs typically takes a lot of time, effort, and money. It typically takes ten to fifteen years for a compound to be approved after it has been discovered. The process starts off in the laboratory with basic research into thousands of possible molecules and identifying molecules that can be developed further. After this, the candidates will be tested in preclinical studies to evaluate their safety, toxicity range, and engage in biological activity through laboratory and animal models [5].

If the results from the preclinical studies are positive, then the drug will undergo human clinical trials in three main phases:

1. Phase One: Study the safety, dosage range and side effects of the drug in a small number of healthy subjects or patients.

2. Phase Two: Confirm that the drug works and continue studying the drug's safety in a larger study population of patients.

3. Phase Three: Study the drug's efficacy, side effects, and effectiveness compared to other available drugs in a large study population.

After completing a successful clinical trial, the company would need to submit a complete dataset to the governing regulatory body (for instance, FDA for U.S. Drugs, or EMA for European Drugs) for the drug to be approved for use. Once the drug has been approved, post-marketing studies (phase four) continue to collect data and evaluate the long-term effects of the drug.

Developing a new drug is an expensive process, usually costing one or more billion dollars. Reasons why it is so expensive include failed trials of drug candidates and lost opportunities. High drug failure rates contribute significantly to the overall R&D costs, because many drug candidates do not progress through the development process past the early stages [6].

Pharmaceutical companies will typically prioritize drug development in high commercial therapeutic areas such as cancer, cardiovascular disease, diabetes, and autoimmune disease. These indications have larger patient populations and typically yield better economic returns. Conversely diseases of poverty, including some tropical and neglected diseases that are prevalent in lower-income countries receive less attention because they do not generate as much profit as drugs targeting high-income regions. The disparity in drug development for high- versus low-income populations illustrates a clear conflict between commercial motivation and the global health need.

To reduce R&D costs and financial risks, pharmaceutical companies frequently form partnerships with other companies, enter into licensing agreements with other companies, or acquire biotechnology companies. Collaborative research with academic institutions also helps to alleviate the financial burden and to increase the capacity for innovation [7].

1.1.2 Clinical Trial Complexity

Over time, clinical trials have become significantly more complex than before. New regulations from regulatory agencies require more comprehensive data for both safety and efficacy. In addition, there have been increasing demands from the public for more safety and efficacy data just as ethical standards have also risen. Clinical study designs usually include multiple endpoints, adaptive designs, biomarker analysis, and long-term follow up periods which put a strain on logistics and budgets.

The major hurdle to conducting clinical trials is in recruiting participants. Delays in conducting studies are often due to getting eligible patients who satisfy the very strict inclusion and exclusion criteria to take part in the study. Recruiting participants is particularly problematic in rare diseases, children, and those patients who fall into very specific genetically targeted groups who will receive personalized therapy.

Globalization also adds to the challenge of conducting clinical trials. Many studies are conducted internationally in many different countries so that studies are more representative of the patients being studied and that patient recruitment can occur much faster than studying patients in a single country alone [8]. While this way of conducting clinical trials has improved the generalizability of the study's results, it has increased regulatory variability, language barriers, cultural differences, and logistics involved with recruitment.

In addition, ethical considerations arise too. All clinical studies must receive Institutional Review Board (IRB) and/or Ethics Committee approval of the study protocols to ensure the rights and safety of study patients are protected. The process of informed consent, data privacy laws governing the conduct of studies, and the monitoring of adverse events that occur during the conduct of studies requires careful attention to detail and compliance.

Furthermore, as data management becomes more complex, clinical development is producing increasing amounts of electronic data, portable monitoring systems, imaging technologies, and lab equipment), maintaining the integrity of that data, protecting it from cyber threats, and ensuring compliance with regulations all require the use of advanced infrastructure and/or highly qualified personnel [9].The combination of these factors has resulted in lengthy timelines and increasing costs for clinical trials, making the management of clinical trials a key component of success in the pharmaceutical industry.

1.1.3 Innovation and Technological Integration

The evolution of technology has changed the landscape of research and development in pharmaceuticals. Breakthroughs in biotechnology, genomics, proteomics, and molecular biology, as well as advances in understanding disease pathology at both a cellular and genetic level, enable scientists to create more specific therapies that target disease processes in a more accurate way. The knowledge gained through these scientific advancements allows scientists to develop targeted therapies and biologics to treat diseases with greater efficacy and fewer adverse effects than traditional small molecule drugs.

Artificial intelligence (AI) and machine learning are changing the way drugs are discovered. Using AI algorithms, researchers can analyze large data sets to discover potential drug candidates, predict how they will interact with one another at different molecular levels, and create optimized designs for clinical trials [10]. By utilizing these technologies, researchers can significantly decrease the time spent on initial stages of drug discovery processes and can make decisions more accurately than ever before.

Genomic sequencing and identification of various biological markers have created opportunities to provide personalized medicine, rather than "one-size-fits-all" drugs. This allows for therapies to be customized based on a person's individual genetic profile, thereby increasing the efficacy of the treatment and decreasing the number of patients who experience negative effects from medications. In precision oncology, there are treatments specifically based on the presence or absence of specific genetic mutations.

In addition to advances in research and discovery, improvements in manufacturing technology such as continuous manufacturing and bioprocess optimization enhanced manufacturing efficiencies and the consistency of manufactured products. The use of digital twins and predictive modeling will further improve the ability to assure that the quality of manufactured products meets or exceeds customer expectations while minimizing waste through better control processes [11].

Nevertheless, the requirement of substantial capital investment to implement these technologies along with an appropriately skilled workforce make adopting these technological advancements difficult for small to mid-sized pharmaceutical companies as they will have a much greater challenge than larger companies due to the larger companies having access to both greater

financial resources and advanced technology. Because of these rapid changes in technology, it is necessary to continue to learn about new technologies, upgrade infrastructure, and adapt to regulatory requirements.

Despite these obstacles, innovation is still the principal driver of growth and competitiveness in the pharmaceutical industry. By integrating these leading-edge technologies into their R&D processes, companies will have the capability to improve speed of drug development, decrease costs of drug development, and offer innovative therapies to patients around the globe.

1.2 REGULATORY ENVIRONMENT

The regulation of the pharmaceutical industry is among the most significant influence on the external environment. Since all medicines impact human health, safety, and well-being, governing bodies across the world enforce regulations that govern the safety, efficacy, and quality of pharmaceutical products. Regulatory oversight helps to protect the public's health and create confidence in the use of medical products. Additionally, regulations have a large effect on development timelines, operating expenses, market access, and total business strategy for pharmaceutical companies.

1.2.1 Stringent Approval Processes

Prior to the commercialization of any pharmaceutical product, it is necessary to obtain approval from a regulatory authority, whether national or regional. Other nations have regulatory agencies with similar purposes but may have different data requirements and processes.

In general, the regulatory process involves the submission of a comprehensive application package that documents all data obtained during preclinical studies, clinical trials, manufacturing processes, and quality control measures [12]. The regulators review the product's benefit/risk ratio such as whether the product's therapeutic benefits outweigh any potential adverse reactions, as part of their evaluation, and the regulators must conduct a thorough review of the safety, efficacy and statistical data, pharmacokinetics, labelling information, and production methods associated with the product.

While these lengthy approval processes are a necessary protective measure for patients, they can also lengthen the time required for a product's development. The length of time it takes to receive regulatory reviews can be lengthy, especially when additional data is requested and/or additional clarifications are needed. Additionally, companies must respond and comply with changing FDA or EMA regulatory guidelines, which may impose new or different requirements for clinical trial endpoints, data transparency, or manufacturing specifications. As such, development costs may increase, and product time to market or profitability as well as competitive positioning it is impacted negatively consequently.

To respond to urgent healthcare requirements, regulatory authorities may adopt fast-tracking, priority review or conditional approval as a way of providing a quicker path to market for medications. Nevertheless, even with expedited processing, there is still a need to provide significant evidence in addition to maintaining post-approval monitoring for the products.

1.2.2 Compliance and Pharmacovigilance

Legal accountability for pharmaceutical companies does not end when their drugs are approved for sale. They are bound by law to continue their compliance efforts related to safety, quality, and the reporting of information about their products. After-market surveillance (sometimes called Phase IV monitoring) is an important source of information about rare or long-term side effects that might not have been discovered during pre-approval clinical trials [13].

Pharmacovigilance (PV) systems require companies to collect, evaluate, and report unexpected harm caused by a drug to health regulatory authorities. Healthcare professionals and patients are also able to report adverse events that help provide further safety monitoring. Regulatory authorities may also require companies to change a drug's label, restrict its use, or withdraw it from the market if there is sufficient evidence of significant safety issues.

Compliance with Good Manufacturing Practices (GMPs) is critical in ensuring that pharmaceutical products are consistently manufactured and controlled according to established quality standards. Inspections of the factory, office space, and records associated with drug manufacture are performed by regulatory authorities to confirm that the company is maintaining proper documentation, validating the equipment used, properly applying sanitation procedures, and implementing quality systems.

If a company is in non-compliance with regulatory requirements, it can have dire consequences for that company. Penalties include financial penalties, import bans, recalls, or suspensions of the company's drug manufacturing license [14]. Most

significantly, the loss of trust, damaged reputation, and/or loss of business from supply interruption beyond direct loss of sales. Trust is difficult to restore in the healthcare industry.

1.2.3 Regulatory Harmonization

Due to the international nature of pharmaceutical trade, harmonization of regulatory standards has been increasingly important. The existence of different types of regulatory requirements across different countries makes it more difficult to trade internationally and creates duplicate clinical trial requirements; consequently, delays patient access to medications.

Harmonization efforts are focused on aligning technical requirements and streamlining the approval process. The World Health Organization and other organizations that promote international drug standards such as safety, quality and effectiveness play an important role in this effort. Other countries also have developed collaborative efforts such as sharing information, performing joint inspections and utilizing the same guidelines for drug approvals across countries.

One of the benefits of having harmonized regulations is that they will help facilitate multinational clinical trials and will reduce time-to-market for new drug product approvals [15]. Harmonization will result in an overall lowering of compliance costs and provide for a more efficient process for companies to submit regulatory data. In addition, when drugs are harmonized and approval processes coordinated, it will result in increased availability of innovative therapies to patients throughout the world.

Nevertheless, complete standardization of regulations will be very difficult to achieve due to varying healthcare systems and legal systems within each country. Additionally, emerging markets may have some difficulty in achieving full regulatory capacity due to lack of financial resources.

1.3 INTELLECTUAL PROPERTY RIGHTS AND PATENTS

The existence and longevity of the pharmaceutical sector hinge upon Intellectual Property Rights (IPRs). Companies that create drugs invest considerable sums of money, wait extended periods of time, and face significant chances of failing to create a new drug [16]. Therefore, companies heavily depend on patent protection as a tool for obtaining financial return on their investments in innovation. In addition to rewarding the developer for creating an innovative product through patent protection, the intellectual property framework must consider the social goal of enabling people to access medicines affordably. The interaction of these principles establishes the basis for price and distribution strategies associated with global pharmaceutical corporations, as well as the shape of international trade relations.

1.3.1 Patent Protection

Pharmaceutical companies are granted patents that give them exclusive rights to make, market, and sell newly developed drugs for a set amount of time, generally 20 years from the filing date. To prevent other companies from producing or selling the drug without authorization, no competitor can do so during this time, meaning that the inventor company will recoup R&D expenses, defray the large costs associated with dealing with failed development projects, and earn the profits necessary to support future innovations [17]. However, most effective patent terms are much shorter than the twenty-year time frame because a lot of it will go toward performing clinical trials and receiving required regulatory approvals. Because of this, pharmaceutical companies will often seek patent term extensions or supplementary protection certificates to recover any lost time on their patents because of the delay between the date filed and the date, they can bring their products to market.

Additionally, in addition to getting the primary patent on an active pharmaceutical ingredient, companies will frequently obtain additional secondary patents on the formulations of the active ingredient, the processes used to make the drug, the method of delivering the drug, and all new uses for the drug. This practice is referred to as "evergreening", and many companies do this to continue extending the length of time that the company can hold its patent as long as possible and to delay generic entry into the market. Though these practices are legal, some critics contend that this practice stifles competition and keeps drug prices high.

The provision of patents can help spur creativity when it comes to developing new treatments for high-risk medical conditions/areas like cancer treatment, the rare disease category and modern biological drugs [18]. If a company did not have patent protection, they may be less likely to take chances on investing money into expensive and unpredictable research developments. Therefore, patents are extremely valuable tools used by pharmaceutical manufacturers as part of an overall strategy for driving innovation within their business models.

1.3.2 Generic Competition

Once the patent has run out on a specific drug, it allows many other producers of that same drug, now called generic versions, to begin marketing their version of the product. A generic will contain the same active ingredient, dosage form, strength, and route of administration as the original branded product; however, generic sales will usually be done at a much lower price than the original branded product.

The introduction of generic competitors greatly affects the economics of the marketplace. After multiple generic manufacturers have entered the marketplace [19], the price of the original brand product typically declines from 50%-90%. This drop in price will dramatically increase access for patients and reduce the overall healthcare costs incurred by governments and insurers. When a manufacturer loses patent protection for a product, and consequently begins to lose revenue from that product, this event is commonly referred to as the "patent cliff."

The entry of generics has resulted in an increased level of competition within the pharmaceutical industry. Manufacturers must take steps to manage their product portfolios to offset the revenue losses incurred as marketed products lose patent protection. Companies may do this by either investing in improved formulations of their existing products, entering new geographic markets usually in developing countries, developing and producing biologic versions of their existing products, or investing in new research and development programs.

Biosimilars, which are generic-like versions of existing biologics, are becoming a large and rapidly developing segment of the competitive marketplace for generics. Because biology is considerably more complex than traditional generic products, the introduction of biosimilars will contribute to increased levels of competition and cost savings throughout the healthcare systems of the world.

1.3.3 Compulsory Licensing

Compulsory licensing allows local producers to manufacture a patented drug without permission from the patent owner in specific situations such as public health emergencies, for example pandemics, or when essential medicines are too costly for the population to buy.

International trade treaties recognize compulsory licensing as lawful to protect people's health by helping to ensure access to medicines that can save lives, especially in countries with low or middle incomes [20]. Nevertheless, some believe that using compulsory licensing too often could lead to reduced incentives for drug companies to develop new medicines and decrease their investment in risky projects that require a lot of money to develop.

Different pharmaceutical companies will use their strategies to consider the possibility of compulsory licensing: through varying pricing schemes, entering into voluntary licensing agreements or finding local partners who would produce the product for them so they can retain their presence in that market, yet still allow for good access to those medicines. International negotiations and diplomatic issues generally come into play when deciding whether to use compulsory licensing, signaling the intersection between intellectual property, public health, and the world of geopolitics.

1.4 ECONOMIC FACTORS

The economics of the country dramatically impact on the structure, performance, and strategic direction of the pharmaceutical industry. Medicines are both needed by healthcare practitioners as well as sold commercially and, therefore, economic factors affect research priorities, pricing strategies, investment decisions, and globalization plans [21]. Macroeconomic stability is determined by the broadest set of macroeconomic factors that influence pharmaceutical industry growth and sustainability including national income levels; healthcare finance systems; and competitive economic realities.

1.4.1 Healthcare Expenditure

The primary factor affecting pharmaceutical demand is expenditure on healthcare at the national or federal level. Countries with strong economies as measured by gross domestic products and functioning publicly funded or privately funded healthcare systems spend more dollars to have access to resources needed to administer medical services, provide adequate insurance, and purchase pharmaceuticals. Therefore, they are usually able to implement more innovative costly treatments, including biologics, gene therapy treatments, and other complex oncology therapies.

There is also a large connection between publicly funded healthcare systems and privately funded (insurance-based) healthcare systems; therefore, these systems have a strong influence on levels of consumption of pharmaceuticals. Patients who have access to a greater amount of prescription medication may be referred to as having broad insurance coverage; correspondingly, the ability for patients to access prescription medications increases the size of the pharmaceutical market when it is in a high-income country. Conversely, in low- or middle-income countries, patients often have limited access to higher-priced medications due to substantial out-of-pocket costs, which leads these patients to primarily purchase generics [22].

Finally, demographic changes can also affect increased healthcare expenditures. In developed countries, as the population ages, the demand for treatment of chronic illnesses such as heart disease, diabetes, Alzheimer's Disease, and cancer will increase. Future demographic shifts will lead to sustained growth in total pharma expenditures and create significant challenges for government health expenditures in providing the additional cost of new drug treatments. While an economic downturn or fiscal constraint may cause a decrease in healthcare spending, price caps, delayed reimbursement, and restricted utilization and or eligibility for pharmaceuticals could also result from macroeconomic instability, thus demonstrating a strong connection between macroeconomic conditions and the performance of the pharmaceutical marketplace.

1.4.2 Pricing and Reimbursement Policies

Drug prices remain among the most hotly contested topics in global health care. Pharmaceuticals typically try to price their products in such a way that they can cover their expenses for research and development and turn a profit [23]. On the other hand, governments and insurers routinely try to keep drug prices affordable and to ensure they will not be a burden on the overall health care budget.

Many countries have regulatory agencies that negotiate prices for drugs prior to approving them for reimbursement. Health Technology Assessment agencies assess the clinical effectiveness and cost-effectiveness of new therapies in relation to existing treatments. Only new drugs with enough therapeutic benefit will be included on the reimbursement list.

The use of value-based pricing models in health care systems throughout the world is becoming more common. These models tie together the reimbursement for a drug with the outcomes produced by it from a therapeutic standpoint, as well as its effectiveness in practice. As an example, a drug will be given a greater reimbursement rate if it results in an appreciable increase in survival or decreases in hospitalizations, whereas the reimbursement will be limited for an inadequate outcome.

The practice of reference pricing is also prevalent and involves comparing the prices of drugs with the prices in other countries, and to similar drugs within the same class of therapeutic drug. This pricing strategy is intended to prevent excessive pricing; however, it can lead to reduced profit margins for pharmaceutical companies. Business strategy development can be affected by pricing pressures. Companies with very strict price controls in their country may not decide to launch new pharmaceuticals in that country and others can negotiate risk sharing agreements as a way of achieving access to the marketplace. Price and reimbursement policies will determine the available revenue streams and will impact the company's ability to expand globally.

1.4.3 Market Competition

In recent years, competition among pharmaceutical companies has been changing rapidly. Generics are one of the players entering the marketplace with less expensive versions of established drugs, and when that happens, other drugs are also affected as well as the prices of those brand-name drugs [24]. One example of this competition would be when a generic drug is introduced onto the market, a company that has a biosimilar available as an alternative will have reduced revenues for their brand-name products.

Biosimilars are beginning to appear and provide competition for expensive biological products, making them more cost effective, creating challenges to previously established brands. There is also other competition that occurs from the therapeutic substitutes such as medical devices and/or lifestyle type diseases and therapies. There are new technologies that provide opportunities for new enterprises such as biotechnology companies and digital health companies to participate in certain therapeutic areas.

To maintain current market positioning and to enhance competitive advantages pharmaceutical companies are using mergers and acquisitions as a strategy. For example, when a large pharmaceutical company acquires a small biotechnology firm it gives them the opportunity to grow their product pipeline, access new technology, and diversify their risk. Likewise, pharmaceutical companies commonly pursue the use of strategic alliances and joint ventures to share and reduce R&D expenditures while also accelerating product development.

Pharmaceutical companies also employ additional strategies to maintain competitiveness in a changing environment such as diversifying portfolios, expanding into emerging markets, and investing early-stage high-growth therapeutic areas [25].

1.5 TECHNOLOGICAL ADVANCEMENTS

Advances in technology are among the most important changes affecting the pharmaceutical industry today. The rapid evolution of biopharmaceuticals, digital health systems, artificial intelligence (AI), and advanced manufacturing technologies is changing the processes by which medicines are discovered, developed, manufactured, and delivered. These innovations are enhancing the speed and efficiency of these processes while also enabling the development of more targeted, efficacious, and patient-specific therapies. However, these advancements require investments, expertise, and regulatory changes to be implemented effectively.

1.5.1 Biotechnology and Biologics

Biologic products are revolutionizing the pharmaceutical industry through biotechnology by allowing for a new class of pharmaceuticals known as biologics which are complex medications that come from living systems. Biologics differ from traditional small-molecule drugs because they come from biological sources as opposed to being made via chemical synthesis like small-molecule drugs. Examples of biologics include monoclonal antibodies, proteins created using recombinant DNA technology, vaccines, gene therapy, and cell-based treatments. Biology has very high specificity because they typically target specific molecular pathways that cause disease.

In addition to their specificity, biology is the fastest growing class of pharmaceuticals on a global basis due in part to the fact that they are becoming an increasingly important therapeutic solution for people with various diseases including cancer, autoimmune diseases, rare diseases and metabolic diseases. They are also more effective treatments with fewer side effects than traditional therapies due to their ability to more specifically target mechanisms that cause disease.

Biology also requires very sophisticated and controlled manufacturing processes. The production of biologics usually includes living cell cultures, bioreactors and very complex purification systems. The technical challenges and costs associated with ensuring the safety, stability and consistency of biologics are extreme; even small variations in the manufacturing process can have significant impacts on the quality and safety of a biologic product [26].

Compounding this issue is the increasing demand for biosimilars, which are products that are highly similar to already approved biology. The ability of a biosimilar manufacturer to demonstrate their; or their product's similarity to an approved biologic product without jeopardizing the safety of the biosimilar product requires significant analytical and clinical data and evaluations. As a result, biology and biotechnology require specialized expertise, infrastructure and regulatory oversight which is a significant component in determining investment strategies in the pharmaceutical sector.

1.5.2 Digital Health and Artificial Intelligence (AI)

Pharmaceutical companies are being transformed digitally at a rapid pace. Digital health technologies generate large amounts of real-world health data; these technologies include EHRs, wearable technologies, mobile health applications, telemedicine, etc. This data is beneficial for improving clinical studies, continuously monitoring patients, and post-marketing surveillance for pharmaceutical drugs.

AI and machine learning provide companies with powerful tools for drug discovery and development. Companies can use AI-driven platforms to rapidly analyze large biological datasets to identify possible drug targets, predict how molecules will interact, and identify which compounds to use in drug development. This allows for much quicker and cheaper initial research than was previously possible, allowing more drugs to come to market more rapidly.

Digital tools are also improving patient recruitment, remote monitoring of patients, and data collection in clinical trials [27]. Decentralized (also called virtual) clinical trials, when coupled with telemedicine and wearable technology, allow greater accessibility and remove geographical barriers for clinical trial participants. In addition, AI algorithms can assist companies in identifying suitable clinical trial candidates and providing insight into how they will respond to treatments.

While there are many advantages to using digital technologies in addition to R&D, such as enhancing supply chain management and improving operational efficiency, there are also some drawbacks, most notably that digital technology requires large investment in securing sensitive patient information from cyber threats. Predictive analytics, for example, is used to forecast

demand, track levels of inventory and identify disruptions. As a result, solutions such as blockchain are being considered to improve transparency and eliminate counterfeit medications and lastly, regulatory frameworks must evolve if they are going to evaluate evidence generated by AI and validate digital health solutions since current frameworks do not guarantee that the output is accurate, reliable or safe for patients.

1.5.3 Manufacturing Innovations

The pharmaceutical industry relies heavily on innovations in manufacturing technologies to improve efficiency, quality, and overall manufacturing efficiency [28]. Spotting the decline of traditional batch manufacturing is currently being supplemented, or even completely replaced, by continuous manufacturing systems. Continuous manufacturing allows manufacturers to produce without interruption, enjoy a greater degree of process control, and shorten the time required to manufacture a product.

The use of automation and robotics is becoming increasingly common within pharmaceutical manufacturing facilities as automated systems will reduce the chance that a human will make an error, increase the degree of precision in manufacturing, and assist in ensuring that products meet strict quality standards. Manufacturers can now monitor their manufacturing processes with the use of real-time analytics and process analytic technology to identify any deviations from established processes and to ensure consistent quality of all products manufactured.

3D printing technologies are also being developed for use in the pharmaceutical manufacturing industry. This technology has the potential to produce individualized dosage forms that are specific to the needs of the individual patient, especially in the case of treating children or individuals with rare diseases.

As environmental regulations continue to get stricter, sustainable manufacturing processes and methods are becoming more important. Implementing energy-efficient production techniques, reducing waste, and using green chemistry in the manufacturing process will provide cost savings, as well as help manufacturers reduce their impact on the environment.

However, investing in advanced manufacturing technologies typically requires a significant investment of capital, as well as skilled technical personnel and regulatory approval to implement changes in manufacturing processes. For smaller companies, the cost associated with implementing many of these innovations can be prohibitive.

1.6 GLOBALIZATION AND SUPPLY CHAIN DYNAMICS

The advent of globalization has had a huge effect on the pharmaceutical industry, with its extensive global supply chains being created. Globalization has improved operational efficiencies/cost effectiveness and provided opportunities for market expansion; however, these benefits are counter-balanced by increased operational risk through the complexity of regulations associated with conducting business on an international scale. Obtaining raw materials, manufacturing active ingredients, formulating, packaging, and distributing pharmaceuticals occur in multiple countries; therefore, managing the entire supply chain becomes an integral component of overall business strategy [29].

1.6.1 International Trade

The global pharmaceutical supply chain is characterized by a high level of integration. Active Pharmaceutical Ingredients (APIs), which make up most drugs, are often produced in countries like India and China because of the lower costs, abundant skilled workers, and established facilities. After APIs are made, the finished drug (dosage) forms can be manufactured and/or packaged in other countries before being sold throughout the world.

Government agreements on international trade and other cross-border cooperation enable international trade in pharmaceuticals to flow freely throughout the world. Many international pharmaceutical companies have manufacturing facilities, research sites, and distribution systems in multiple countries. Global integration reduces manufacturing costs, increases efficiency in the production of pharmaceuticals, and expands access to medicines.

Due to conflicting regulations, tariffs, intellectual property laws, and quality standards between countries, international trade will be subject to different standards and requirements [30]. Differences in regulatory frameworks may lead to delays and increase compliance risk. In addition, factors such as political instability, trade relations, or export restrictions can adversely affect the ability of pharmaceuticals and their raw materials to be delivered, which directly impacts the functioning of health care systems across the world.

1.6.2 Supply Chain Vulnerabilities

Globalization has many advantages, including economic benefits; however, it has also revealed a wide range of vulnerabilities related to the pharmaceutical industry's supply chain. The COVID-19 pandemic provided a clear example of how disruptions to key manufacturing sites, international transportation systems, and cross-border limitations severely hamper the ability to access medicine when needed. Manufacturing sites were forced to shut down due to pandemic containment measures, low employee counts, and export bans on raw materials that are critical for medicines. As such, the pandemic highlights the significant risks associated with having a high reliance on a small number of geographic locations to produce active pharmaceutical ingredients.

The pharmaceutical supply chain is also threatened by various forms of disruption, such as natural disasters, political instability, cyber-attacks, and logistical congestion. Any disruption to the supply of key raw materials can halt production and impact patient access to life-sustaining medications. In response, many pharmaceutical companies are implementing supply chain resiliency strategies such as diversifying sources, increasing local/regional manufacturing capacity, developing strategic stockpiles, and developing digital tracking systems for improved transparency. In addition, several governments are encouraging domestic production of critical medicines with the goal of reducing dependency on foreign sources [31]. As a result, supply chain risk management has become a cornerstone of pharmaceutical strategy, balancing cost-efficiency with reliability and security.

1.6.3 Emerging Markets

Pharmaceutical firms have a vast range of opportunities for growth in developing markets throughout Asia/Africa/Latin America due mainly to the growth in population, urbanization, middle class and improved access to medical facilities. Due to this rapid growth within the health sector, there will be a surge in pharmaceutical products being purchased both innovatively and generically throughout India/Brazil/Indonesia/Nigeria.

Another contributing factor for increased pharmaceutical use in developing nations is the increased health insurance coverage + additional government provisions. These markets also pose many challenges, including differences in regulatory agencies' transparency/maturity, strong pressure established by governments to ensure affordability and maintain costs + weak enforcement of IP laws.

Cultural or arising access problems, limited distribution, infrastructure, retailers distribute and maintain their pharmaceutical products. Thus, companies need to modify their marketing avenues, pricing strategies, and approach their respective business partners depending on the region they are entering.

1.7 SOCIOPOLITICAL AND ETHICAL FACTORS

Along with financial and technical factors, the pharmaceutical industry is influenced at a broader level by the sociology, politics, and ethics that surround it. Corporate image, government policy, and ethical standards impact the pricing of drugs, as well as the effect that these have on the ability of companies to succeed in the marketplace [32]. With greater accountability to society and more visibility than ever before, companies are being held accountable for their profits as well as their social responsibilities.

1.7.1 Public Perception and Trust

Long-term success in the pharmaceutical industry is dependent on maintaining public trust. People rely on medicines to help their health and/or save their lives so having public confidence and providing transparency about how products are developed is extremely important. The better that the public views the company, and its products in particular, the better brand reputation, support of product adoption, and stronger relationship that will be developed between companies and healthcare providers/regulators.

However, when there are challenging issues such as high drug pricing, aggressive marketing tactics, secret clinical trial results, and/or adverse drug reactions, it could cause the public to lose all confidence in the pharmaceutical industry. As a result of media and social media, public scrutiny of the pharmaceutical industry is very high now, and there is a lot of information that is being shared, both accurate and inaccurate, at a rapid pace.

Pricing issues are particularly sensitive topics because life-saving drugs can become unavailable to individuals who cannot afford them. In these situations, public criticism will normally escalate and may result in regulators acting or there will be political

pressure to reduce drug prices [33]. Therefore, to preserve public trust, pharmaceutical companies must demonstrate transparency in clinical trial data, ethical marketing practices, and embody corporate social responsibility.

As a result, the pharmaceutical industry must communicate clearly and honestly, practice proactive risk management and do so ethically as they strive to uphold their credibility on a global basis in view of the high level of visibility today.

1.7.2 Ethical Clinical Practices

Ethics have always been a part of clinical research, but they are particularly important now due to the increase in international pharmaceutical companies conducting clinical trials. These trials must be conducted in accordance with ethical principles that protect the rights, safety and dignity of research participants. The basis for ethical research includes informed consent, confidentiality, and voluntary participation.

Equitable participant selection is also critical, and efforts should be made to ensure that no vulnerable/exploitable populations are included in the research studies. Therefore, when selecting participants, the researcher must ensure that there is fair representation of all people in the population being studied based on age, gender, ethnicity and socioeconomic status.

Research studies will have an ethics committee or an institutional review board to review the study protocol to ensure that it complies with the ethical standards to which all researchers and institutions must adhere. Research studies conducted in low- and middle-income global regions require even greater scrutiny regarding ethical conduct; therefore, it is the researcher's responsibility to ensure that all participants fully understand the potential risks and benefits of the research and that the research being conducted will provide value to the population in the study's host country.

If ethical guidelines are not adhered to, it can wreak havoc on any clinical research study—from a legal perspective, reputational harm, and the potential for losing regulatory approvals [34]. For this reason, ethics is not only a moral imperative for pharmaceutical companies; it is also a strategic imperative.

1.7.3 Global Health Equity

One of the largest ethical difficulties that the pharmaceutical industry faces is the need to balance the profit motive by providing equitable access to life-saving medications. While companies devote a significant amount of money to research and development and desire a financial return on their investments in drug/vaccine development; there are millions of people around the globe who do not have access to some of the most basic treatments using price as a barrier.

In addition, the global health crisis such as COVID-19 spotlighted discrepancies in the distribution of vaccines and other drugs between countries deemed to be high-income versus those considered low-income. Many debates surrounding issues such as patent protection and differential pricing, between the two groups; and a voluntary licensing agreement along with a technology transfer initiative arises from this situation during an emergency.

Recently pharmaceutical companies have become increasingly involved with global health efforts through tiered pricing models; donations of medications or vaccines; and partnerships with international organizations. Critics of these efforts have indicated that greater systemic reform is needed to provide equitable long-term access to life-saving medications [35].

To accomplish global health equity, all stakeholders need to work together, i.e. governments, international organizations, industry and civil society. As we continue this journey, we hope to find solutions that will provide incentives for innovation, while at the same time ensuring that new medical treatments are made available to people throughout the world.

1.8 ENVIRONMENTAL AND SUSTAINABILITY CONSIDERATIONS

The importance of Environmental Sustainability is becoming increasingly evident in the pharmaceutical sector. Increasing global consciousness over issues like climate change, pollution, and depletion of resources has created an ever-increasing amount of pressure from regulators, investors, and consumers for the pharmaceutical sector to reduce its environmental impact. The sustainability movement has previously been viewed as a corporate social responsibility program. However, today, sustainability is a key component of corporate long-term strategy and risk management.

1.8.1 Environmental Impact

To produce pharmaceuticals, a very complicated and often hazardous level of chemicals is used. If these chemicals are not handled correctly, they create hazardous waste and produce toxic substances as by-products, which become a part of our environment.

Using various chemicals to manufacture active pharmaceutical ingredients, solvents, reagents, and intermediates will create a significant amount of energy in their manufacturing processes because they require various levels of energy and toxic chemicals to produce each product. When pharmaceuticals are disposed of improperly, they will create an environmental hazard and cause contamination of the environment. Some trace amounts of chemicals found in pharmaceuticals have been found to have an adverse effect on the environment through land and water systems, and wildlife; some of these trace chemicals create ecological disruption, while others cause antibiotic resistance. The amount of energy that some manufacturers use also creates a significant carbon emissions problem, creating a massive environmental impact.

Local governments and some international agencies are developing and implementing more stringent environmental regulations regarding emissions into the environment; handling and disposal of waste; and usage of resources [36]. For pharmaceutical manufacturers to comply, they will have to invest capital to build and utilize advanced waste treatment systems, pollution control technologies, and environmental monitoring programs. Although these improvements will increase operating costs, if pharmaceutical manufacturers do not comply with local and/or international environmental regulations, they risk being fined, having their facility shut down, and/or having their reputation destroyed.

The importance of measuring environmental performance is increasing to investors; this is due, in part, to the growing number of evaluation frameworks for Environmental, Social, and Governance purposes. Pharmaceutical manufacturers are going to be required to disclose their sustainability performance metrics to investors and clients and demonstrate that they are working toward carbon neutrality and resource efficiency.

1.8.2 Sustainable Practices

Pharmaceutical companies have begun to implement more sustainable operational practices throughout their value chain to deal with worldwide environmental challenges. Chemical manufacturers that use the principles of green chemistry in designing processes will reduce the potential for harm by reducing the use of dangerous chemicals, minimizing waste produced, and increasing the energy efficiency of chemical processes. By optimizing reaction conditions and using safer raw materials in their reactions, pharmaceutical manufacturers can reduce both their environmental footprint and their production costs [37].

The adoption of renewable energy has also emerged as a growing trend in recent years. Many pharmaceutical companies are moving to the use of solar, wind, and other forms of renewable energy to power their production facilities to reduce their greenhouse gas emissions. Energy-efficient technologies, smart building technologies, and sustainable logistics practices further help to reduce carbon footprint.

Some of the strategies manufacturers can use to reduce their waste include recycling solvents, reducing packaging materials, and enhancing water conservation systems. Advanced wastewater treatment technologies can help to keep pharmaceutical residues from being released into natural ecosystems. Packaging is being re-designed by many companies to use biodegradable or recyclable materials.

While many sustainability initiatives include improvements to the manufacturing processes, some sustainability initiatives include the responsible sourcing of raw materials and partnerships with environmentally responsible suppliers. By working together through these sustainability initiatives, pharmaceutical companies can not only minimize the impact of their actions on the environment but also build a stronger brand reputation and comply with regulatory requirements.

Finally, and probably more critically, environmental sustainability will be a strategic imperative for every company in the future, as it will be the bridge connecting superior economic performance with greater ecological responsibility, thus allowing for greater resilience in a resource-constrained global environment.

1.9 IMPACT OF GLOBAL HEALTH CRISES

The effects of global health crises are profound and immediate for the pharmaceutical industry. Worldwide pandemics, infectious diseases, or global crises can change research priorities, regulatory pathways, and marketplace demand very quickly

[38]. Of the most recent crises, COVID-19 provided a strong example of how the pharmaceutical industry can promote rapid access to innovative vaccines and therapies and work together globally for those goals.

The COVID-19 Pandemic showcased the ability of the pharmaceutical industry to adapt to rapidly developing new vaccines and therapies to combat COVID-19. The COVID-19 vaccine was developed, manufactured, and approved by regulatory agencies through emergency use authorization within a year of the identification of SARS-CoV-2. Regulatory agencies used streamlined processes, such as accelerated approvals, rolling reviews, and emergency use authorizations, to ensure rapid access to therapeutic options while still safeguarding the process of evaluating their safety.

Public or private partnerships were critical during the pandemic. Governments offered funds, logistical support, and procurement guarantees, while pharmaceutical companies provided scientific expertise and manufacturing capability. Through international collaboration among research institutions, biotech companies, and multinational pharmaceutical companies, research and production of resources for COVID-19 occurred rapidly through clinical trials and appropriate large-scale manufacturing.

There were also many serious concerns that developed because of weaknesses exhibited within the global supply chain, indicating the necessity for diversified manufacturing and the need to strategically stockpile essential pharmacy items. The pandemic also accelerated the conversations around the world surrounding vaccine equity, intellectual property rights, and equitable global access to life-saving measures.

Long-term investment priorities have changed with the emergence of the pandemic. Funding and investment are shifting toward areas such as infectious disease research, vaccine platform development, antiviral treatment creation, and construction of infrastructures to prepare for future pandemics [39]. Furthermore, policymakers are amending regulatory structures to allow quicker responses to similar health emergency situations while still prioritizing the safety of patients through continued oversight throughout the process.

In conclusion, global health crises are catalysts for innovation, regulatory reform, and structural change within the pharmaceutical industry. They highlight the importance of the pharmaceutical industry's role in protecting global health from health disasters and identify both the strengths and weaknesses in the industry.

1.10 COMPETITIVE STRATEGIES AND INDUSTRY STRUCTURE

Due to the intense competition and need for continuous innovation that exists within the Pharmaceutical Industry, companies must continuously employ various strategies to maintain their viability and profit. These strategies include enhancing their position in the market, expanding their product pipelines, and reducing their level of exposure to financial risk. The structure of this industry is comprised of many different types of companies, including large multinational corporations, smaller-cap companies, biotech's, and generics, all of which have created a dynamic competitive landscape.

1.10.1 Mergers and Acquisitions

In the pharmaceutical industry, mergers and acquisitions are very common as methods for gaining new technologies or drugs and gaining access to skilled employees [40]. This is common for large pharmaceutical companies to purchase small biotech start-ups and companies as a means of obtaining access to innovative drug candidates, advanced technologies and specialized expertise.

M&A allows companies to broaden their drug research pipeline, enter a new therapeutic area, and make up for revenue losses caused by patent expiration. By acquiring a company, a firm can obtain a delayed candidate drug that has already completed a stage of development, which reduces the time involved with developing the drugs through internal research.

Throughout the M&A process, companies can run into problems associated with large amounts of money being spent and significant integration challenges. Cultural differences, organizational restructuring and redundant pipelines create operational complexities. Even though M&A poses some risks for companies, M&A remains one of the primary strategies firms use to stay competitive in a very dynamic environment.

1.10.2 Strategic Alliances

Collaboration among Pharma Companies, Universities, Biotech Companies, and Research Organizations is key to cooperative innovations. Partnerships between universities and industries help to convert basic science into usable commercial products. These collaborations typically combine an academic research environment and funding and development from the industry.

Public-private partnerships (PPPs) are especially important in the development of vaccines, rare diseases, and neglected tropical diseases [41]. Through the sharing of risk and resources, the models of collaboration allow for the rapid advancement of research while addressing unfulfilled medical needs.

Both contract research organizations (CROs) and contract manufacturing organizations (CMOs) are part of strategic alliances that allow pharmaceutical companies to delegate different parts of the company, such as conducting clinical trials and producing goods, to others. This provides increased flexibility and decreases fixed operational costs.

Strategic alliances foster knowledge sharing; reduce duplication of effort; and help to promote speed of innovation and are therefore important aspects of pharmaceutical companies' strategies in general.

1.10.3 Diversification

A strategy for mitigating risk and achieving revenue stability involves implementing diversification. To achieve this, many pharmaceutical companies have a diversified portfolio that includes therapeutic areas such as oncology, cardiology, infectious disease, neurology, and immunology. The goal of diversifying a portfolio into multiple therapeutic areas is to decrease the risk of dependency on a single product or disease state.

Another critical strategy employed by most pharmaceutical companies is the geographic diversification of their business. Pharmaceutical companies that have expanded their operations into emerging markets reduce their commercial risk and take full advantage of the growth opportunity presented by the developing healthcare systems in those markets [42]. In addition, some pharmaceutical companies are also diversifying into related industries such as medical devices, consumer healthcare products, and digital health.

Finally, investments in diversifying into biologics, biosimilars, and personalized medicine platforms allow pharmaceutical companies to continue to adapt to the constantly evolving technological landscape. With a diversified portfolio, pharmaceutical companies will be better able to withstand market volatility and changes in regulation caused by new government oversight.

1.11 EMERGING TRENDS SHAPING THE FUTURE

Pharmaceuticals are moving into a new and different period due to advances in the sciences, digital technology, and the way patients expect to receive care. Trends toward understanding, diagnosing, and treating disease are changing rapidly. New therapies will be available for greater benefit to patients, whereas these changes will involve large investments, changes in regulations, and the consideration of ethics.

1.11.1 Personalized Medicine

In contrast to the conventional "one-size-fits-all" model of treatment, personalized medicine—often referred to as precision medicine—has emerged as a new paradigm of individualizing treatment based on individual characteristics such as genetic makeup, lifestyle and nature of disease. Advancements in genomics, molecular biology and biomarker research have made it possible for therapies to be tailored based on the genetic characteristics of everyone [43].

As genomic sequencing technologies are developed and continue to improve, so do their turn-around time, the time between collecting a specimen and getting results, and cost-effectiveness. Consequently, clinicians are now able to identify genetic mutations associated with disease. For example, in the case of oncology, targeted therapies can be used based on the genetic alterations found in the cancer cells. By doing so, patients receiving those treatments will likely achieve better results and reduce the amount of unneeded side effects.

Companion diagnostics are an important component of personalized medicine as they help identify those patients who are most likely to benefit from a particular drug. As a result of the growing interest in personalized medicine and the fact that most companies are conducting diagnostic development in parallel to their drug development, the patient outcomes are improved.

While personalized medicine improves the clinical outcomes for patients, some challenges associated with it exist. Smaller patient populations may create smaller markets, and availability of the infrastructure for conducting diagnostic tests may not be readily available in many areas [44]. Furthermore, the development cost of a diagnostic test may create a need to develop new pricing models that both allow for the high cost of development and have price points accessible by many patients.

1.11.2 Gene and Cell Therapy

Gene and cell therapies (GCT) represent one of the most revolutionary advances in the field of medicine today. Both are designed to either cure or provide potential cures by eliminating diseases at the genetic level rather than simply managing symptoms. Gene therapy manipulates cell's genetic material and gene function in a patient by introducing, deleting, or changing specific genetic material which improves function of a defective gene. Alternatively, cell therapy manipulates, modifies, or transplants a living source cellular material such as stem cells into a patient for purposes of creating normal function.

Although these advanced modalities have shown promise for treating rare genetic disorders, certain types/varieties of cancers, and conditions that were considered untreatable until recently, they also present challenges. The manufacturing process associated with developing GCT can be complex and may require specialized facilities and options for individual patients. Due to the complexity of developing GCT treatment, the cost sometimes associated with GCT can be very high, leading to questions concerning reimbursement [45]. Regulatory agencies must also establish the framework needed to assess long-term efficacy and safety of these therapies. Regardless of the challenges that GCT's present, the explosive growth of gene and cell therapy pipelines suggests that these technologies will be an integral part of the future of medicine.

1.11.3 Artificial Intelligence

The advent of Artificial Intelligence (AI) is having a dramatic impact on pharmaceutical research and operations. Predicative algorithms developed using AI can analyze enormous amounts of biological and chemical data at once to help identify promising targets for drug development, as well as provide predictions for the behavior of molecules and optimal compound selection. This process will shorten the drug development cycle at an early stage and lower the odds of having to deal with expensive failures.

During the clinical development process, AI is utilized in predictive modelling for patient stratification [46]. This allows clinical sites to identify patients that will be most likely to respond positively to a specific treatment option. There are also numerous machine learning tools that support the development of clinical trial designs, as well as providing the right amount of dosing for a particular patient population and ensuring that the patient remains compliant with the terms of the study.

In addition to research and development, AI will assist in the improvement of pharmaceutical manufacturing efficiencies, quality control processes, and supply chain management using predictive analytics and real-time monitoring. Automated systems can identify where abnormalities exist, where production errors will occur, and what the demand will be for a specific product.

Integration of AI technologies will require high-quality data, very advanced computational infrastructures, and clarifications regarding regulatory requirements. Ethical issues associated with data privacy, transparency of algorithms, and biases related to algorithm results will also need to be taken into consideration. Despite these challenges, AI is an agent of transformation capable of dramatically reducing the amount of time and expense involved in the drug development process.

1.11.4 Real-World Evidence

Real World Evidence (RWE) is defined as clinical evidence that comes from sources that are not traditional RCTs [47]. This source of data includes electronic health records (EHR), insurance claims databases, patient registries and wearables. This RWE provides information about how medicines perform in real-world clinical settings on a variety of patients with differing societal backgrounds.

Increasingly, regulators are considering RWE as part of their assessment of a drug's safety, efficacy and performance after market entry. RWE can be used to support companies with additional labelling, post-market safety surveillance and reimbursement. In addition, RWE can help pharmaceutical companies to show payers the value their products are providing with respect to real-world outcomes and cost effectiveness.

Digital Health Technologies and wearables contribute significantly to the generation of RWE by continuously tracking patients' health metrics. Collectively, this real-time information improves pharmacovigilance and provides important data for post-

marketing safety assessments. Although RWE is complementary to traditional RCTs, there still exist challenges in assuring data quality, standardization of reporting and protection of privacy. Establishing appropriate analytic frameworks and regulatory guidance will be vital for maximizing the value of real-world data.

1.12 CHALLENGES AND OPPORTUNITIES

The pharmaceutical sector is at a crossroads and is facing huge challenges as well as unique opportunities. R&D costs are increasing, there are greater regulatory requirements, patents are expiring and there are pricing constraints from public scrutiny [48]. Furthermore, governments and health systems are expecting all pharmaceuticals to be affordable, transparent, and return to demonstrable therapeutic value.

The challenges associated with balancing the return on investment for shareholders while meeting public health objectives are growing in complexity. Investors demand sustainable returns and society expects that there will be fair access to life-saving medicines. Issues relating to pricing, the protection of intellectual property rights, and health equity continue to define industry policies and create public perceptions of pharmaceuticals.

At the same time, there are technological advances in genomics, biotechnology, artificial intelligence, and digital health that have the potential to transform the sector. Innovative collaboration through research models, public private partnerships, and global scientific networks will help to accelerate innovation. Increasingly flexible regulatory frameworks will accommodate adaptive approval processes and allow the use of real-world evidence in regulatory reviews, allowing for faster access to medicine.

Emerging markets provide opportunities for growth and will serve pivotal to the use of diversification strategies to mitigate the risks that are associated with patent expirations and competition in the marketplace [49]. Sustainable manufacturing practices and environmental responsibility will also enhance the long-term strength of the company and the overall nature of its business.

The future of the pharmaceutical industry hinges on the ability of the industry to capture the balancing act of integrating innovation with affordability, efficiency with ethics, and profit with social responsibility. Through scientific advancements, partnerships and collaborations, and putting the focus on the patient, the industry will continue to work on the many challenges to the continually evolving world while also further improving the health status of the world.

CONCLUSION

The pharmaceutical industry consists of several moving parts that influence the direction of the industry. These parts include R&D expenses, regulatory changes, patent and intellectual property laws, economic and global changes, technology, ethics, and the environment. With the constant rapid pace of change in health care and science, the industry will continually have to change how it works to remain socially responsible. It is important that policymakers and industry leaders work together to set boundaries that promote new ideas while also making sure people have access to important medications. There are many factors that influence the pharmaceutical industry, either positively or negatively, which are important to understand to improve health care around the world.

DECLARATION CONFLICTING INTEREST

The author(s) declare that there are no conflicts of interest related to the research, authorship, or publication of this article.

FUNDING

This research (Ho SM) was supported by INTI International University.

ACKNOWLEDGMENT

This research work was financially supported by INTI International University (Ho SM).

REFERENCES

[1] Agrawal M. The effect of National Environment on global competitiveness, the case of the pharmaceutical industry. J Transnatl Manag Dev. 1999; 4: 27-48.

[2] Jan T, Ajar N, Babita S, Negi R, Sheikh S. Probiotic formulations for human health: current research and future perspective. Journal of Applied Biology & Biotechnology. 2024; DOI: 10.7324/jabb.2024.166024

[3] Takawira B, Pooe R. Supply chain disruptions during COVID-19 pandemic: Key lessons from the pharmaceutical industry. S Afr J Bus Manag. 2024; 55: DOI: https://doi.org/10.4102/sajbm.v55i1.4048.

[4] Shen K, Yan M, Tzeng G. Exploring R&D influences on financial performance for business sustainability considering dual profitability objectives. Sustainability. 2017; 9: https://doi.org/10.3390/su9111964.

[5] Van N. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic to Transl Sci. 2019; 4: 845-854.

[6] DiMasi J. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics. 2002; 20: doi: 10.2165/00019053-200220003-00001.

[7] Srinivas T, Varaprasad R. Innovation through collaboration: Advancing higher education research. Res Rev Adv Robot. 2023; 7: 7-16.

[8] Luo J, Wu M, Chen W. Geographical distribution and trends of clinical trial recruitment sites in developing and developed countries. J Health Informatics Dev Ctries. 2017; 11: https://www.jhidc.org/index.php/jhidc/article/view/157.

[9] Campos J, Sharma P, Jantunen E, Baglee D. The challenges of cybersecurity frameworks to protect data required for the development of advanced maintenance. Proc CIRP. 2016; 47: 222-227.

[10] Vamathevan J, Clark D, Czodrowski P, Dunham I. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019; 18: 463-477.

[11] Fantozzi I, Santolamazza A, Loy G, Schiraldi M. Digital twins: Strategic guide to utilize digital twins to improve operational efficiency in Industry 4.0. Future Internet. 2025; 17: https://doi.org/10.3390/fi17010041.

[12] Gelis L, Stoeckert I, Podhaisky H. Digital Tools—regulatory considerations for application in clinical trials. Ther Innov Regul Sci. 2023; 57: 769-782.

[13] Dieck G, Sharrar R. Preparing for safety issues following drug approval: pre-approval risk management considerations. Ther Adv Drug Saf. 2013; 4: 220-228.

[14] Rodwin M. Do we need stronger sanctions to ensure legal compliance by pharmaceutical firms? Food Drug Law J. 2015; 70: 435-452

[15] Gomase V, Sharma R, Dhamane S. Global Analysis of Regulatory Frameworks and Drug Safety Standards in the Drug Approval Process. Curr Drug Saf. 2025; doi: 10.2174/0115748863392869250827042742.

[16] Myers S, Baker A. Drug discovery—an operating model for a new era. Nat Biotechnol. 2001; 19: 727-730.

[17] Bakker G. Money for nothing: How firms have financed R&D-projects since the Industrial Revolution. Res Policy. 2013; 42: 1793-1814.

[18] Pegram C, Neill D, Chang Y, Hekkel, F. Risk factors for unilateral cranial cruciate ligament rupture diagnosis and for clinical management in dogs under primary veterinary care in the UK. Vet J. 2023; 292: 105952.

[19] Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy. 2004; 68: 47-54.

[20] Harika A. Patents, Power, and the Right to Health: How Pharmaceutical Intellectual Property Governance Undermines Equitable Access to Essential Medicines. SSRN. 2026; https://ssrn.com/abstract=6024394 or http://dx.doi.org/10.2139/ssrn.6024394

[21] Schoonveld E. The price of global health: drug pricing strategies to balance patient access and the funding of innovation. Routledge. 2020.

[22] Kaplan W, Ritz L, Vitello M, Wirtz V. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. Health Policy. 2012; 106: 211-224.

[23] Scherer F. Pricing, profits, and technological progress in the pharmaceutical industry. J Econ Perspect. 1993; 7: 97-115.

[24] Sinha M. Costly gadgets: barriers to market entry and price competition for generic drug-device combinations in the United States. Minn J Law Sci Technol. 2022; 23: https://scholarship.law.umn.edu/mjlst/vol23/iss1/7.

[25] Lloyd C, Lesley A, Ralf S. An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23). Lancet Microbe. 2026; DOI: 10.1016/j.lanmic.2025.101288 External Link.

[26] Laptos T, Omersel J. The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies. Exp Ther Med. 2018; 15: 3161-3168.

[27] Rosa C, Marsch L, Winstanley E, Brunner M. Using digital technologies in clinical trials: current and future applications. Contemp Clin Trials. 2021; 100: doi: 10.1016/j.cct.2020.106219.

[28] Connor T, Lawrence X, Lee S. Emerging technology: A key enabler for modernizing pharmaceutical manufacturing and advancing product quality. Int J Pharma. 2016; 509: 492-498

[29] Singh R, Kumar R, Kumar P. Strategic issues in pharmaceutical supply chains: a review. Int J Pharma Healthc Mark. 2016; 10: 234-257.

[30] Maskus K. Regulatory standards in the WTO: Comparing intellectual property rights with competition policy, environmental protection, and core labor standards. World Trade Rev. 2002; 1: 135-152.

[31] Handfield R, Finkenstadt D, Schneller S, Godfrey A. A commons for a supply chain in the post-COVID-19 era: the case for a reformed strategic national stockpile. Milbank Q. 2020; 98: 1058-1090.

[32] Resnik D. Developing drugs for the developing world: An economic, legal, moral, and political dilemma. Dev World Bioeth. 2001; 1: 11-32

[33] Carpenter D. The political economy of FDA drug review: processing, politics, and lessons for policy. Health Aff. 2004; 23: 52-63.

[34] Banerjee S, Banerjee D, Pooja D, Kulhari H, Jadhav H. Unethical practices in research designs. In Principles of Research Methodology and Ethics in Pharmaceutical Sciences. CRC Press. 2024; 47-80.

[35] Hanney S, Straus S, Holmes B. Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. Health Res Policy Syst. 2022; 20: https://doi.org/10.1186/s12961-022-00883-6.

[36] Yannik B, Lapkin A, Jan B. Pollution prevention in the pharmaceutical industry. Int J Sustain Eng. 2012; 6: https://doi.org/10.1080/19397038.2012.730070.

[37] Ogbuagu O, Mbata A, Balogun O, Oladapo O. Sustainable pharmaceutical supply chains: Green chemistry approaches to drug production and distribution. IRE J. 2024; 8: 761-767.

[38] Olliaro P, Torreele E. Global challenges in preparedness and response to epidemic infectious diseases. Mol Ther. 2022; 30: 1801-1809.

[39] Graham B, Sullivan N. Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. Nat Immunol. 2018; 19: 20-28.

[40] Rossi M, Yedidia S, Raviv A. Mergers and acquisitions in the hightech industry: a literature review. Int J Organ Anal. 2013; 21: 66-82.

[41] Aerts C, Sunyoto T, Tediosi F, Sicuri E. Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Policy. 2017; 121: 745-754.

[42] Tannoury M, Attieh Z. The influence of emerging markets on the pharmaceutical industry. Curr Ther Res Clin Exp. 2017; 86: 19-22.

[43] Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism. 2015; 64: S16-S21.

[44] Mabey D, Peeling R, Ustianowski A, Perkins M. Diagnostics for the developing world. Nat Rev Microbiol. 2004; 2: 231-

240.

[45] Rouce R, Grilley B. How to democratize cell and gene therapy: a global approach. Mol Ther. 2025; 33: 2082-2090.

[46] Azuaje F. Artificial intelligence for precision oncology: beyond patient stratification. NPJ Precis Oncol. 2019; 3: https://doi.org/10.1038/s41698-019-0078-1.

[47] Dang A. Real-world evidence: a primer. Pharm Med. 2023; 37: 25-36.

[48] Price W. Making do in making drugs: innovation policy and pharmaceutical manufacturing. BCL Rev. 2014; 55: 491-562.

[49] Iyer G, LaPlaca P, Sharma A. Innovation and new product introductions in emerging markets: Strategic recommendations for the Indian market. Ind Mark Manag. 2006; 35: 373-382.